169 related articles for article (PubMed ID: 37949024)
1. Autologous hematopoietic stem cell transplantation is superior to alemtuzumab in patients with highly active relapsing multiple sclerosis and severe disability.
Vaisvilas M; Kaubrys G; Kizlaitiene R; Taluntiene V; Giedraitiene N
Mult Scler Relat Disord; 2023 Dec; 80():105096. PubMed ID: 37949024
[TBL] [Abstract][Full Text] [Related]
2. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
[TBL] [Abstract][Full Text] [Related]
3. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life.
Braun B; Fischbach F; Richter J; Pfeffer LK; Fay H; Reinhardt S; Friese MA; Stellmann JP; Kröger NM; Heesen C; Häußler V
Mult Scler Relat Disord; 2024 Feb; 82():105414. PubMed ID: 38176284
[TBL] [Abstract][Full Text] [Related]
4. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
[TBL] [Abstract][Full Text] [Related]
5. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
6. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
Zhukovsky C; Sandgren S; Silfverberg T; Einarsdottir S; Tolf A; Landtblom AM; Novakova L; Axelsson M; Malmestrom C; Cherif H; Carlson K; Lycke J; Burman J
J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):189-194. PubMed ID: 33106366
[TBL] [Abstract][Full Text] [Related]
8. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America.
Burt RK; Tappenden P; Han X; Quigley K; Arnautovic I; Sharrack B; Snowden JA; Hartung D
Mult Scler Relat Disord; 2020 Oct; 45():102404. PubMed ID: 32731201
[TBL] [Abstract][Full Text] [Related]
9. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
Burt RK; Han X; Quigley K; Helenowski IB; Balabanov R
J Neurol; 2022 May; 269(5):2513-2526. PubMed ID: 34633525
[TBL] [Abstract][Full Text] [Related]
10. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
Front Immunol; 2020; 11():668. PubMed ID: 32431694
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
[TBL] [Abstract][Full Text] [Related]
12. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
[TBL] [Abstract][Full Text] [Related]
14. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
15. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
[TBL] [Abstract][Full Text] [Related]
16. Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
Kvistad CE; Lehmann AK; Kvistad SAS; Holmøy T; Lorentzen ÅR; Trovik LH; Kristoffersen EK; Bø L; Torkildsen Ø
Mult Scler; 2024 May; 30(6):751-754. PubMed ID: 38345003
[TBL] [Abstract][Full Text] [Related]
17. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
18. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis.
Häußler V; Ufer F; Pöttgen J; Wolschke C; Friese MA; Kröger N; Heesen C; Stellmann JP
Ann Clin Transl Neurol; 2021 Jun; 8(6):1269-1278. PubMed ID: 33949790
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
[TBL] [Abstract][Full Text] [Related]
20. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
